Treatment of kidney allograft with chronic antibody-mediated rejection using tocillizmab .

Phase 1

• Conditions: Chronic antibody-mediated rejection; kidney transplantation, chronic antibody-mediated rejection

• Registration Number: JPRN-jRCTs031180443
• Lead Sponsor: SHISHIDO SEIICHIRO

Brief Summary

We treated three patients with chronic antibody-mediated rejection by tocilizumab therapy. No adverse events due to tocilizumab administration occurred in three patients. The kidney function in two patients (case #1 and #3) gradually decreased and they started inhemodialysis after finishing the scheduled tocilizumab therapy. Although the histological damage in glomerulus and tubules unchanged in the case #2, the kidney function of this patient was stabilized 18 months after finishing the therapy.

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-03-28
• Study Completion: 2020-03-03
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 3

Inclusion Criteria

1. A patient with biopsy-proven chronic antibody-mediated rejection (CAMR) with positive donor-specific anti-HLA antibodies.
2. A patient which was resistant to the standard care of treatment for CAMR.
3. eGFR of patients > 30ml/min/1.73m2
4. A patient who willing to attend this study.

Exclusion Criteria

1. A patient with severe infection
2. A patient with active tuberculosis
3. A patient with malignancy
4. A patient having allergy to tocillizumab
5. A patient with severe complication which may affect the outcome of this study.
6. A patient with pregnancy

Study & Design

• Study Type: Interventional
• Study Design: Not specified